Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment

Ko, Jung Hwa; Meyer, April N.; Haas, Martin; Donoghue, Daniel J.

doi:10.18632/oncotarget.27859

Cited by 12 publications

(9 citation statements)

References 49 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tyrosine kinases are mediators of intracellular signaling pathways that control cell growth, migration, and invasion. Some examples in this group include Dasatinib, Cabozantinib, and Sunitinib [ 133 , 134 , 167 ]. ENDOTHELIN RECEPTOR ANTAGONISTS are Atrasentan and Zibotentan.…”

Section: Standard and Novel Therapies Used In 3d Models Of Pcmentioning

confidence: 99%

Let’s Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer

Petrić

Sabol

2023

IJMS

View full text Add to dashboard Cite

Prostate cancer (PC) is the third most frequently diagnosed cancer worldwide and the second most frequent in men. Several risk factors can contribute to the development of PC, and those include age, family history, and specific genetic mutations. So far, drug testing in PC, as well as in cancer research in general, has been performed on 2D cell cultures. This is mainly because of the vast benefits these models provide, including simplicity and cost effectiveness. However, it is now known that these models are exposed to much higher stiffness; lose physiological extracellular matrix on artificial plastic surfaces; and show changes in differentiation, polarization, and cell–cell communication. This leads to the loss of crucial cellular signaling pathways and changes in cell responses to stimuli when compared to in vivo conditions. Here, we emphasize the importance of a diverse collection of 3D PC models and their benefits over 2D models in drug discovery and screening from the studies done so far, outlining their benefits and limitations. We highlight the differences between the diverse types of 3D models, with the focus on tumor–stroma interactions, cell populations, and extracellular matrix composition, and we summarize various standard and novel therapies tested on 3D models of PC for the purpose of raising awareness of the possibilities for a personalized approach in PC therapy.

show abstract

Section: Standard and Novel Therapies Used In 3d Models Of Pcmentioning

confidence: 99%

Let’s Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer

Petrić

Sabol

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The authors used various tyrosine kinase inhibitors (PD166866, BGJ398, and dovitinib) to inhibit FGFR signaling. ALDH7A1 expression was upregulated in DU145, PC3, and iPS87 spheroids in response to dovitinib treatment, suggesting its potential role in activating the pro-survival mechanisms [ 159 ].…”

Section: Aldh7a1mentioning

confidence: 99%

The Multifaceted Role of Aldehyde Dehydrogenases in Prostate Cancer Stem Cells

Püschel

Dubrovska

Gorodetska

2021

Cancers

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are the only tumor cells possessing self-renewal and differentiation properties, making them an engine of tumor progression and a source of tumor regrowth after treatment. Conventional therapies eliminate most non-CSCs, while CSCs often remain radiation and drug resistant, leading to tumor relapse and metastases. Thus, targeting CSCs might be a powerful tool to overcome tumor resistance and increase the efficiency of current cancer treatment strategies. The identification and isolation of the CSC population based on its high aldehyde dehydrogenase activity (ALDH) is widely accepted for prostate cancer (PCa) and many other solid tumors. In PCa, several ALDH genes contribute to the ALDH activity, which can be measured in the enzymatic assay by converting 4, 4-difluoro-4-bora-3a, 4a-diaza-s-indacene (BODIPY) aminoacetaldehyde (BAAA) into the fluorescent product BODIPY-aminoacetate (BAA). Although each ALDH isoform plays an individual role in PCa biology, their mutual functional interplay also contributes to PCa progression. Thus, ALDH proteins are markers and functional regulators of CSC properties, representing an attractive target for cancer treatment. In this review, we discuss the current state of research regarding the role of individual ALDH isoforms in PCa development and progression, their possible therapeutic targeting, and provide an outlook for the future advances in this field.

show abstract

“…Studies on PCSCs have identified many signaling pathways that positively regulate the PCSC properties, which include PTEN/PI3K/AKT [ 222 , 228 ], NF-kB [ 224 ], Notch [ 137 , 158 , 226 ], Hedgehog [ 226 ], Wnt/β-catenin [ 230 , 250 , 257 , 259 , 286 , 314 ], JAK/STAT [ 235 ], β4 integrin [ 239 ], hypoxia through HIF1α [ 246 ], IL-30/IL-27p28 [ 254 , 266 ], BRCA1/EZH2 [ 271 ], and FGF/FGFR [ 308 ]. Also reported are positive molecular regulators of PCSCs including, among others, MYC [ 234 ],STAT3[ 235 , 237 , 241 , 245 , 286 , 296 ],ERG[ 236 , 297 ],BMI-1[ 139 , 249 ], Skp2 [ 251 ], YAP1 [ 253 ], CXCL12γ [ 255 ], LIN28B [ 248 , 295 ], ASPM [ 259 ], NANOG [ 122 , 125 , 135 , 137 , 142 , 143 , 150 , 156 , 262 , 263 ], SOX2 [ 270 , 276 ], OCT4 [ 270 ], CXCR2 [ 272 ], SOX9 [ 277 ], HOTAIR [ 296 ], BMP5 [ 298 ], and MUC-1 [ 279 , 306 , 318 ].…”

Section: Introductionmentioning

confidence: 99%

Understanding and targeting prostate cancer cell heterogeneity and plasticity

Tang¹

2022

Seminars in Cancer Biology

View full text Add to dashboard Cite

Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment

Cited by 12 publications

References 49 publications

Let’s Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer

Let’s Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer

The Multifaceted Role of Aldehyde Dehydrogenases in Prostate Cancer Stem Cells

Understanding and targeting prostate cancer cell heterogeneity and plasticity

Contact Info

Product

Resources

About